NDAORALTABLET
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
6
Mechanism of Action
Estrogen Receptor Antagonists
Pharmacologic Class:
Estrogen Receptor Antagonist
Clinical Trials (5)
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Started Feb 2026
600 enrolled
Breast Neoplasm Female
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Started Oct 2022
8,000 enrolled
Breast Neoplasms
A Study of Imlunestrant (LY3484356) in Healthy Women
Started Sep 2022
20 enrolled
Healthy
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
Started Jul 2022
113 enrolled
Healthy
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
Started Jul 2022
27 enrolled
Hepatic InsufficiencyHealthy
Loss of Exclusivity
LOE Date
Jul 11, 2039
162 months away
Patent Expiry
Jul 11, 2039
Exclusivity Expiry
Sep 25, 2030